Biglycan Up-regulated Vascular Endothelial Growth Factor (VEGF) Expression and Promoted Angiogenesis in Colon Cancer

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Nov 6

PMID 25371074

Citations 39

Authors

Xiaojing Xing

Xiaohu Gu

Tianfei Ma

Huinan Ye

Affiliations

Soon will be listed here.

Abstract

Biglycan is an important component of the extracellular matrix, which belongs to the small leucine-rich proteoglycan family. Recent studies have shown that biglycan expression is elevated in many tumor tissues and implies poor prognosis, such as colon cancer. However, the molecular mechanism of biglycan in colon cancer has not been investigated. The present study aimed to investigate the effects of biglycan on vascular endothelial growth factor (VEGF) expression in colon cancer cells and on tumor angiogenesis in vivo. Biglycan overexpression vectors were constructed, and the stable biglycan overexpression in human colon cancer cell lines (HCT116 cells) was established by G418 screening. The stable cell clones were subsequently used to initiate tumor xenografts in nude mice. Our results showed that biglycan overexpression notably up-regulated the levels of VEGF in colon cancer cells, which was further confirmed by immunohistochemistry analysis in the xenograft colon tumors. Moreover, high levels of biglycan promoted angiogenesis and colon tumor growth, as evidenced by the increased cell viability, colon tumor size, and weight, as well as the CD34 expression. Additionally, we found that the extracellular signal-regulated kinase (ERK) signaling pathway was activated by biglycan in colon cancer cells. The ERK inhibitor PD98059 dramatically reversed the increased expression of VEGF induced by biglycan. Taken together, our results indicated that biglycan up-regulated VEGF expression in colon cancer cells and promoted tumor angiogenesis. Biglycan-mediated VEGF regulation may correlate with the activation of the ERK signaling pathway. Therefore, biglycan may be a promising target for anti-angiogenic therapy for cancer.

Citing Articles

The Landscape of Small Leucine-Rich Proteoglycan Impact on Cancer Pathogenesis with a Focus on Biglycan and Lumican.

Berdiaki A, Giatagana E, Tzanakakis G, Nikitovic D Cancers (Basel). 2023; 15(14).

PMID: 37509212 PMC: 10377491. DOI: 10.3390/cancers15143549.

High-throughput sequencing-based metagenomic and transcriptomic analysis of intestine in piglets infected with .

Won K, Kim D, Shin D, Hur J, Lee H, Heo J J Anim Sci Technol. 2023; 64(6):1144-1172.

PMID: 36812005 PMC: 9890335. DOI: 10.5187/jast.2022.e73.

Unusual Suspects: Bone and Cartilage ECM Proteins as Carcinoma Facilitators.

Sorvina A, Antoniou M, Esmaeili Z, Kochetkova M Cancers (Basel). 2023; 15(3).

PMID: 36765749 PMC: 9913341. DOI: 10.3390/cancers15030791.

Biglycan Interacts with Type I Insulin-like Receptor (IGF-IR) Signaling Pathway to Regulate Osteosarcoma Cell Growth and Response to Chemotherapy.

Giatagana E, Berdiaki A, Gaardlos M, Samsonov S, N Tzanakakis G, Nikitovic D Cancers (Basel). 2022; 14(5).

PMID: 35267503 PMC: 8909324. DOI: 10.3390/cancers14051196.

Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.

Maishi N, Sakurai Y, Hatakeyama H, Umeyama Y, Nakamura T, Endo R Cancer Sci. 2022; 113(5):1855-1867.

PMID: 35266253 PMC: 9128192. DOI: 10.1111/cas.15323.

References

Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R . ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell. 2006; 9(1):33-44. DOI: 10.1016/j.ccr.2005.12.021. View

Gangenahalli G, Singh V, Verma Y, Gupta P, Sharma R, Chandra R . Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006; 15(3):305-13. DOI: 10.1089/scd.2006.15.305. View

Ajili F, Kacem M, Tounsi H, Darouiche A, Enayfer E, Chebi M . Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol. 2012; 36(5):336-42. DOI: 10.3109/01913123.2012.672847. View

Wadhwa S, Embree M, Bi Y, Young M . Regulation, regulatory activities, and function of biglycan. Crit Rev Eukaryot Gene Expr. 2005; 14(4):301-15. DOI: 10.1615/critreveukaryotgeneexpr.v14.i4.50. View

Hogan F, Krishnegowda N, Mikhailova M, Kahlenberg M . Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007; 143(1):58-65. DOI: 10.1016/j.jss.2007.03.080. View

Takahashi Y, Kitadai Y, Bucana C, Cleary K, Ellis L . Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18):3964-8. View

Wang B, Li G, Zhang S, Wang Q, Wen Y, Tang H . Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med (Maywood). 2011; 236(11):1247-53. DOI: 10.1258/ebm.2011.011124. View

Berendsen A, Pinnow E, Maeda A, Brown A, McCartney-Francis N, Kram V . Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix Biol. 2013; 35:223-31. PMC: 4139970. DOI: 10.1016/j.matbio.2013.12.004. View

Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K . VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011; 17(7):347-62. DOI: 10.1016/j.molmed.2011.01.015. View

10.

Lin P, Sankar S, Shan S, Dewhirst M, Polverini P, Quinn T . Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 1998; 9(1):49-58. View

11.

Weber C, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F . Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology. 2001; 121(3):657-67. DOI: 10.1053/gast.2001.27222. View

12.

Liu Y, Li W, Li X, Tai Y, Lu Q, Yang N . Expression and significance of biglycan in endometrial cancer. Arch Gynecol Obstet. 2013; 289(3):649-55. DOI: 10.1007/s00404-013-3017-3. View

13.

Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P . VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999; 247(2):495-504. DOI: 10.1006/excr.1998.4359. View

14.

Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K . Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer. 2012; 106(6):1214-23. PMC: 3304426. DOI: 10.1038/bjc.2012.59. View

15.

Carmeliet P, Jain R . Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249-57. DOI: 10.1038/35025220. View

16.

Liang D, Li F, Fu Y, Cao Y, Song X, Wang T . Thymol inhibits LPS-stimulated inflammatory response via down-regulation of NF-κB and MAPK signaling pathways in mouse mammary epithelial cells. Inflammation. 2013; 37(1):214-22. DOI: 10.1007/s10753-013-9732-x. View

17.

Gu X, Ma Y, Xiao J, Zheng H, Song C, Gong Y . Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. Clin Exp Med. 2011; 12(3):195-9. DOI: 10.1007/s10238-011-0155-4. View

18.

Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y . Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol. 2008; 49(2):207-16. DOI: 10.1016/j.jhep.2008.03.025. View

19.

Pan S, Cheng L, White J, Lu W, Utleg A, Yan X . Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS. 2009; 13(4):345-54. PMC: 6469530. DOI: 10.1089/omi.2009.0008. View

20.

Folkman J, Hanahan D . Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp. 1991; 22:339-47. View